Jason Dunn
Psychiatric/Mental Health · Elizabethtown, KYNPI 1356895916
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.3% of the total across 734 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 10.8% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 734 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$988
- AbbVie$982
- Alkermes, Inc.$945
- Corium, LLC$916
- Otsuka America Pharmaceutical, Inc.$860
- plus $5K from 22 others
What the payments were for
- Food & beverage$10,90298%
- Education$1862%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 94 | $1,203 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 73 | $988 |
| AbbVie | 77 | $982 |
| Alkermes, Inc. | 59 | $945 |
| Corium, LLC | 70 | $916 |
| Otsuka America Pharmaceutical, Inc. | 49 | $860 |
| Teva Pharmaceuticals USA, Inc. | 40 | $654 |
| Lundbeck LLC | 52 | $578 |
| Ironshore Pharmaceuticals Inc. | 37 | $510 |
| Axsome Therapeutics, Inc. | 13 | $486 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $376 |
| Sunovion Pharmaceuticals Inc. | 35 | $368 |
| Vanda Pharmaceuticals Inc. | 18 | $303 |
| Tris Pharma Inc | 13 | $232 |
| Supernus Pharmaceuticals, Inc. | 11 | $201 |
| Johnson & Johnson | 9 | $195 |
| Noven Therapeutics, LLC | 10 | $176 |
| Gilead | 2 | $165 |
| E.r. Squibb & Sons, L.L.C. | 9 | $160 |
| Merck | 9 | $154 |
| Idorsia Pharmaceuticals US Inc | 9 | $149 |
| Almatica Pharma LLC | 7 | $147 |
| Novo Nordisk | 1 | $124 |
| Collegium Pharmaceutical, Inc. | 5 | $94 |
| Edwards Lifesciences | 1 | $42 |
| Vertical Pharmaceuticals, LLC | 3 | $41 |
| Eisai Inc. | 2 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,088 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $111,065 |
| VraylarCariprazine Hcl | 30 | $43,804 |
| RexultiBrexpiprazole | 15 | $23,716 |
| TrintellixVortioxetine Hydrobromide | 16 | $10,542 |
| Lurasidone Hcl | 15 | $5,484 |
| Lisdexamfetamine Dimesylate | 14 | $2,876 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 20 | $2,079 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 31 | $1,599 |
| Aripiprazole | 26 | $1,146 |
| Escitalopram Oxalate | 26 | $1,138 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 22 | $1,017 |
| Quetiapine Fumarate | 32 | $724 |
| Diazepam | 91 | $690 |
| Buspirone Hcl | 55 | $654 |
| Clonazepam | 76 | $591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,203 | $111,06513 claims |
| AbbVieVraylar | $982 | $43,80430 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $860 | $23,71615 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $376 | $10,54216 claims |
| Almatica Pharma LLCSertraline Hcl | $147 | $2818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Elizabethtown
- Amanda MedleyElizabethtown$14K
- Donald BlackburnElizabethtown$8K
- Sandra AubreyElizabethtown$7K
- Cheri FrederickElizabethtown$7K
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.